Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination

Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination Extensive studies have demonstrated that infant immune responses are distinct from those of adults. Despite these differences, infant immunization can elicit protective immune responses at levels comparable to or, in some cases, higher than adult immune responses to many vaccines. To date, only a few HIV vaccine candidates have been tested in infant populations, and none of them evaluated vaccine efficacy. Recent exciting studies showing that HIV-infected infants can develop broad neutralizing antibody responses and that some HIV vaccine regimens can elicit high levels of potentially protective antibodies in infants provide support for the development and testing of HIV vaccines in pediatric populations. In this review, we discuss the differences in adult and infant immune responses in the setting of HIV infection and vaccination. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Vaccine Immunology American Society For Microbiology

Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination

Download PDF

Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination

Martinez, David R.; Permar, Sallie R.; Fouda, Genevieve G.
Clinical and Vaccine Immunology , Volume 23 (2) – Feb 1, 2016

Abstract

Extensive studies have demonstrated that infant immune responses are distinct from those of adults. Despite these differences, infant immunization can elicit protective immune responses at levels comparable to or, in some cases, higher than adult immune responses to many vaccines. To date, only a few HIV vaccine candidates have been tested in infant populations, and none of them evaluated vaccine efficacy. Recent exciting studies showing that HIV-infected infants can develop broad neutralizing antibody responses and that some HIV vaccine regimens can elicit high levels of potentially protective antibodies in infants provide support for the development and testing of HIV vaccines in pediatric populations. In this review, we discuss the differences in adult and infant immune responses in the setting of HIV infection and vaccination.

Loading next page...
 
/lp/american-society-for-microbiology/contrasting-adult-and-infant-immune-responses-to-hiv-infection-and-Ge8bBFmgBj

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Society For Microbiology
Copyright
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
ISSN
1556-6811
eISSN
1556-679X
DOI
10.1128/CVI.00565-15
pmid
26656117
Publisher site
See Article on Publisher Site

Abstract

Extensive studies have demonstrated that infant immune responses are distinct from those of adults. Despite these differences, infant immunization can elicit protective immune responses at levels comparable to or, in some cases, higher than adult immune responses to many vaccines. To date, only a few HIV vaccine candidates have been tested in infant populations, and none of them evaluated vaccine efficacy. Recent exciting studies showing that HIV-infected infants can develop broad neutralizing antibody responses and that some HIV vaccine regimens can elicit high levels of potentially protective antibodies in infants provide support for the development and testing of HIV vaccines in pediatric populations. In this review, we discuss the differences in adult and infant immune responses in the setting of HIV infection and vaccination.

Journal

Clinical and Vaccine Immunology – American Society For Microbiology

Published: Feb 1, 2016

References

  • B-cell responses to vaccination at the extremes of age
  • Mechanisms underlying reduced responsiveness of neonatal neutrophils to distinct chemoattractants
  • Phagocyte function in the neonate: selected aspects
  • Phenotype and function of neonatal DC
  • Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns
  • Neonatal innate TLR-mediated responses are distinct from those of adults
  • The expression of human natural killer cell receptors in early life
  • Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections
  • Natural killer cell responses to infections in early life
  • Defective production of IL-18 and IL-12 by cord blood mononuclear cells influences the T helper-1 interferon gamma response to group B streptococci
  • Cord blood CD16+56− cells with low lytic activity are possible precursors of mature natural killer cells
  • Higher proportions of circulating FOXP3+ and CTLA-4+ regulatory T cells are associated with lower fractions of memory CD4+ T cells in infants
  • Age-related changes in expression of CXCR4 and CCR5 on peripheral blood leukocytes from uninfected infants born to human immunodeficiency virus type 1-infected mothers
  • Memory CD4(+)CCR5(+) T cells are abundantly present in the gut of newborn infants to facilitate mother-to-child transmission of HIV-1
  • Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells
  • Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10
  • Differential modulation of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2
  • Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency
  • Serum levels of IgG subclasses in the normal child. Evaluation by an immunoenzymatic method using monoclonal antibodies
  • APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells
  • Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life
  • Immune response to vaccine adjuvants during the first year of life
  • CpG drives human transitional B cells to terminal differentiation and production of natural antibodies
  • MF59 mediates its B cell adjuvanticity by promoting T follicular helper cells and thus germinal center responses in adult and early life
  • Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant
  • Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin)
  • Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China
  • Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults
  • Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes
  • Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age
  • Oil-in-water emulsion adjuvant with influenza vaccine in young children
  • Development of serum antibodies during early infancy in rhesus macaques: implications for humoral immune responses to vaccination at birth
  • Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants
  • The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya
  • Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants
  • T cell immunity to measles viral proteins in infants and adults after measles immunization
  • The relationship between concentration of specific antibody at birth and subsequent response to primary immunization
  • Transplacentally acquired maternal antibody against hepatitis B surface antigen in infants and its influence on the response to hepatitis B vaccine
  • Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies
  • Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis
    HIV Paediatric Prognostic Markers Collaborative Study Group
  • Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia
  • HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria
  • Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated
  • Ontogeny of anti-human immunodeficiency virus (HIV) antibody production in HIV-1-infected infants
  • Ontogeny of the humoral immune response to human immunodeficiency virus type 1 in infants
  • Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality
  • Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children
  • Delayed generation of antibodies mediating human immunodeficiency virus type 1-specific antibody-dependent cellular cytotoxicity in vertically infected infants. WITS Study Group. Women and Infants Transmission Study
  • Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection
  • Antibodies in HIV-1 vaccine development and therapy
  • Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C
  • Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies
  • Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
  • HIV broadly neutralizing antibody targets
  • Early development of broadly neutralizing antibodies in HIV-1-infected infants
  • Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
  • Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
  • The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
    CHAVI Clinical Core B
  • Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children
  • Detection of HIV-specific cell-mediated cytotoxicity in the peripheral blood from infected children
  • CD8+ T-cell-mediated suppression of HIV replication in the first year of life: association with lower viral load and favorable early survival
  • Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers
  • Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women
    Pediatric AIDS Clinical Trials Group 230 Collaborators
  • Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine
    AIDS Clinical Trials Group 230 Collaborators
  • Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines
  • Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women
  • Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate
  • Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy
  • HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers
  • Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa
  • Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144
  • Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    MOPH-TAVEG Investigators
  • Immune-correlates analysis of an HIV-1 vaccine efficacy trial
  • Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses
  • Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines
  • Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination
  • Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120
  • IgG antibody responses to recombinant gp120 proteins, gp70V1/V2 scaffolds, and a cyclic V2 peptide in Thai phase I/II vaccine trials using different vaccine regimens
  • High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies
  • Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
  • Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
  • Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
  • Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
  • Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
  • HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission
  • Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
  • Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies
  • Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
    NISC Comparative Sequencing Program
  • Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
    NISC Comparative Sequencing Program
  • Rational HIV immunogen design to target specific germline B cell receptors
  • HIV-1 Vaccines. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies
  • Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
  • Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children
  • Therapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC)
  • Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission
  • Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy
  • Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents
    Pediatric HIV/AIDS Cohort Study
  • Early highly active antiretroviral therapy enhances B-cell longevity: a 5 year follow up
  • Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy
  • Viremic relapse after HIV-1 remission in a perinatally infected child
  • Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection